Treatment of Fabry’s Disease with the Pharmacologic Chaperone MigalastatDominique P. Germain, Raphael Schiffmann, Derralynn Hughes et al.|New England Journal of Medicine|2016Cited by 555
Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1‐year Phase 1/2 clinical trialRaphael Schiffmann, Derralynn Hughes, Özlem Göker-Alpan et al.|Journal of Inherited Metabolic Disease|2019Cited by 137
Clinical impact of genomic testing in patients with suspected monogenic kidney diseaseKushani Jayasinghe, Catherine Quinlan, Matthew F. Hunter et al.|Genetics in Medicine|2020Cited by 125
Efficacy of the pharmacologic chaperone migalastat in a subset of male patients with the classic phenotype of Fabry disease and migalastat-amenable variants: data from the phase 3 randomized, multicenter, double-blind clinical trial and extension studyDominique P. Germain, Christopher Viereck, Kathy Nicholls et al.|Genetics in Medicine|2019Cited by 96